# Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

> **NCT00358982** · PHASE2 · TERMINATED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 51 (actual)

## Conditions studied

- Hodgkin's Lymphoma

## Interventions

- **DRUG:** MGCD0103

## Key facts

- **NCT ID:** NCT00358982
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2015-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358982, "Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00358982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*